Table 2. Risk of stroke, TIA, MACE and major bleeding events during vitamin K-antagonist treatment stratified by renal function within the entire population.

Endpoint	No. of events	N/100 py‡ (95% CI)	Crude HR (95% CI)	Adjusted HR (95% CI)
Stroke or TIA
No CKD	19	1.62(1.03–2.54)	ref	ref
Moderate CKD	15	1.20(0.71–1.99)	0.72(0.36–1.41)	0.70(0.35–1.41)
Severe CKD	11	4.24(2.30–7.53)	2.40(1.13–5.07)	2.75(1.25–6.05)
Overall MACE *
No CKD	36	3.48(2.51–4.80)	ref	ref
Moderate CKD	41	3.79(2.80–5.12)	1.06(0.68–1.67)	1.05(0.66–1.67)
Severe CKD	30	15.4(10.95–21.16)	3.78(2.31–6.19)	3.57(2.10–6.06)
Fatal MACE †
No CKD	7	0.64(0.28–1.35)	ref	ref
Moderate CKD	12	1.05(0.58–1.85)	1.68(0.66–4.27)	1.64(0.64–4.17)
Severe CKD	4	1.67(0.50–4.38)	2.09(0.60–7.23)	1.92(0.55–6.67)
Overall major bleeding *
No CKD	46	4.45(3.34–5.89)	ref	ref
Moderate CKD	45	4.11(3.07–5.46)	0.91(0.60–1.37)	0.90(0.59–1.37)
Severe CKD	22	8.84(5.85–13.07)	1.88(1.13–3.14)	1.66(0.97–2.86)
Fatal bleeding †
No CKD	9	0.83(0.41–1.59)	ref	ref
Moderate CKD	8	0.70(0.33–1.40)	0.85(0.33–2.21)	0.82(0.32–2.13)
Severe CKD	4	1.67(0.50–4.38)	1.62(0.49–5.33)	1.52(0.46–5.02)

Definitions: no-CKD  =  estimated glomerular filtration rate (eGFR) >60 ml/min, moderate CKD  =  eGFR 30–60 ml/min, severe CKD  =  eGFR <30 ml/min.

Abbreviations: CKD  =  chronic kidney disease, PY  =  patient years, CI  =  confidence interval, HR  =  hazard ratio, MACE  =  major adverse cardiovascular event, TIA  =  transient ischemic attack.

^‡Reported incidences for patients with an eGFR 30–60 or eGFR >60 ml/min are influenced by sampling of patients matched for age and gender to those with an eGFR <30 ml/min.

* HR adjusted for age, gender, hypertension, the use of platelet-inhibitors, diabetes mellitus and congestive heart failure.

^†HR adjusted for age and gender. Further correcting resulted in non-converging coefficients.